Sandoz Drops Provigil Paragraph IV Certification; Cephalon Drops Litigation
This article was originally published in The Pink Sheet Daily
Executive Summary
Sandoz will convert its ANDA for modafinil to a Paragraph III certification and will not market its generic until Provigil patent expiry in 2014, Cephalon says. However, other generic competition is expected in mid-2006. Sun also drops challenge of Gabitril (tiagabine).